Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1997 1
2010 1
2013 1
2016 1
2017 2
2018 1
2021 2
2022 1
2023 2
2024 2
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab deruxtecan for HER2+ advanced breast cancer.
Lee J, Park YH. Lee J, et al. Future Oncol. 2022 Jan;18(1):7-19. doi: 10.2217/fon-2021-0550. Epub 2021 Nov 26. Future Oncol. 2022. PMID: 34823373 Review.
It is approved in the US with boxed warnings for interstitial lung disease and embryo-fetal toxicity. This review focuses on preclinical, pharmacokinetic and pharmacodynamic data on T-DXd and clinical evidence of its antitumor activity (both as monotherapy an …
It is approved in the US with boxed warnings for interstitial lung disease and embryo-fetal toxicity. This review focus …
Trastuzumab Deruxtecan: A Review in Gastric or Gastro-Oesophageal Junction Adenocarcinoma.
Kang C. Kang C. Target Oncol. 2023 Nov;18(6):981-989. doi: 10.1007/s11523-023-00998-y. Epub 2023 Oct 3. Target Oncol. 2023. PMID: 37787931 Review.
Trastuzumab deruxtecan carries regulatory warnings (including boxed warnings in the USA) for interstitial lung disease/pneumonitis and embryo-foetal toxicity. Current evidence indicates that trastuzumab deruxtecan is an effective treatment option, and is gene …
Trastuzumab deruxtecan carries regulatory warnings (including boxed warnings in the USA) for interstitial lung disease/pneumon …
Pulmonary and pleural pathology: Contributions of Dr. Louis "Pepper" Dehner.
Ritter JH, Hill DA. Ritter JH, et al. Semin Diagn Pathol. 2016 Nov;33(6):450-461. doi: 10.1053/j.semdp.2016.09.001. Epub 2016 Sep 21. Semin Diagn Pathol. 2016. PMID: 27838088 Review.
While many think of him as a pediatric pathologist, he has contributed to the literature across virtually the entire breadth of surgical pathology, and the lung and pleura is no exception. This review will highlight Dr. Dehners contributions to the pulmonary and pleural pa …
While many think of him as a pediatric pathologist, he has contributed to the literature across virtually the entire breadth of surgical pat …
Primary Lung Tumors in Children: Radiologic-Pathologic Correlation From the Radiologic Pathology Archives.
Lichtenberger JP 3rd, Biko DM, Carter BW, Pavio MA, Huppmann AR, Chung EM. Lichtenberger JP 3rd, et al. Radiographics. 2018 Nov-Dec;38(7):2151-2172. doi: 10.1148/rg.2018180192. Radiographics. 2018. PMID: 30422774 Review.
In the neonate and infant, the important considerations include pleuropulmonary blastoma (PPB), infantile fibrosarcoma, and fetal lung interstitial tumor. Among these tumors, imaging findings such as air-filled cysts in type 1 PPB and hom …
In the neonate and infant, the important considerations include pleuropulmonary blastoma (PPB), infantile fibrosarcoma, and fetal …
[Interstitial processes of the lungs in childhood].
Popper H. Popper H. Pathologe. 2017 Jul;38(4):260-271. doi: 10.1007/s00292-017-0280-2. Pathologe. 2017. PMID: 28349192 Review. German.
Interstitial processes in the lungs of children can be due to several underlying diseases. ...In addition, pediatric pulmonologists are often very reluctant to perform lung biopsies due to a lack of a specialized pathologist. In order to make a contribution to the d …
Interstitial processes in the lungs of children can be due to several underlying diseases. ...In addition, pediatric pulmonologists a …
Congenital and perinatal cytomegalovirus lung infection.
Coclite E, Di Natale C, Nigro G. Coclite E, et al. J Matern Fetal Neonatal Med. 2013 Nov;26(17):1671-5. doi: 10.3109/14767058.2013.794207. Epub 2013 May 9. J Matern Fetal Neonatal Med. 2013. PMID: 23570320 Review.
OBJECTIVE: To review the epidemiological, pathogenetic, clinical and therapeutic features of prenatal and perinatal CMV lung diseases. METHODS: Evaluation of all published papers listed on PubMed describing CMV pneumonitis in infants. ...In premature infants, CMV infection …
OBJECTIVE: To review the epidemiological, pathogenetic, clinical and therapeutic features of prenatal and perinatal CMV lung diseases …
Spontaneous Partial Regression of Fetal Lung Interstitial Tumor With A2M::ALK Rearrangement in a Neonate.
Tan-Garcia A, Lee YT, Kuick CH, Soh SY, Chang KT, Merchant K. Tan-Garcia A, et al. Pediatr Dev Pathol. 2024 Mar-Apr;27(2):187-192. doi: 10.1177/10935266231189929. Epub 2023 Oct 11. Pediatr Dev Pathol. 2024. PMID: 37818649 Review.
The differential diagnosis for neonatal primary lung masses includes developmental anomalies and congenital lung tumors. Fetal lung interstitial tumor (FLIT) is a rare benign mesenchymal lesion which presents either antenatally or …
The differential diagnosis for neonatal primary lung masses includes developmental anomalies and congenital lung tumors …
A Review of Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Breast Cancer.
Nguyen X, Hooper M, Borlagdan JP, Palumbo A. Nguyen X, et al. Ann Pharmacother. 2021 Nov;55(11):1410-1418. doi: 10.1177/1060028021998320. Epub 2021 Feb 25. Ann Pharmacother. 2021. PMID: 33629601 Review.
In these trials, the response rate was 60.9% (95% CI = 53.4-68.0) Common adverse effects included fatigue, nausea, vomiting, decreased appetite, constipation, diarrhea, alopecia, neutropenia, anemia, and thrombocytopenia. Serious adverse effects included interstitial lu …
In these trials, the response rate was 60.9% (95% CI = 53.4-68.0) Common adverse effects included fatigue, nausea, vomiting, decreased appet …
Inflammatory myofibroblastic tumors of the lung carrying a chimeric A2M-ALK gene: report of 2 infantile cases and review of the differential diagnosis of infantile pulmonary lesions.
Tanaka M, Kohashi K, Kushitani K, Yoshida M, Kurihara S, Kawashima M, Ueda Y, Souzaki R, Kinoshita Y, Oda Y, Takeshima Y, Hiyama E, Taguchi T, Tanaka Y. Tanaka M, et al. Hum Pathol. 2017 Aug;66:177-182. doi: 10.1016/j.humpath.2017.06.013. Epub 2017 Jul 11. Hum Pathol. 2017. PMID: 28705706 Review.
We report 2 infantile cases of pulmonary tumor carrying a chimeric A2M-ALK gene. A2M-ALK is a newly identified anaplastic lymphoma kinase (ALK)-related chimeric gene from a tumor diagnosed as fetal lung interstitial tumor (FLIT). FLIT is …
We report 2 infantile cases of pulmonary tumor carrying a chimeric A2M-ALK gene. A2M-ALK is a newly identified anaplastic lymphoma ki …
Toxicity and monitoring of immunosuppressive therapy used in systemic autoimmune diseases.
Meyer KC, Decker C, Baughman R. Meyer KC, et al. Clin Chest Med. 2010 Sep;31(3):565-88. doi: 10.1016/j.ccm.2010.05.006. Clin Chest Med. 2010. PMID: 20692548 Review.
Such therapy can stabilize systemic manifestations of connective tissue disease (CTD) and may put the disease into remission, and many of these agents are commonly used to treat CTD-associated interstitial lung disease (ILD). Although these agents have largely revol …
Such therapy can stabilize systemic manifestations of connective tissue disease (CTD) and may put the disease into remission, and many of th …
13 results